{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:17:06Z","timestamp":1762957026985,"version":"build-2065373602"},"reference-count":36,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>A cohort of 650 patients treated for localized prostate cancer (PCa) with CyberKnifeTM ultra-hypofractionated radiotherapy between 2011 and 2018 was retrospectively analyzed in terms of survival, patterns of failure, and outcomes of second-line definitive salvage therapies. The analysis was performed using survival analysis including the Kaplan\u2013Meier method and Cox regression analysis. At a median follow-up of 49.4 months, the main pattern of failure was local\u2013regional failure (7.4% in low-, and 13% in intermediate\/high-risk group at five years), followed by distant metastases (3.6% in low-, and 6% in intermediate\/high-risk group at five years). Five-year likelihood of developing a second malignancy was 7.3%; however, in the vast majority of the cases, the association with prior irradiation was unlikely. The 5-year overall survival was 90.2% in low-, and 88.8% in intermediate\/high-risk patients. The independent prognostic factors for survival included age (HR 1.1; 95% CI 1.07\u20131.14) and occurrence of a second malignancy (HR 3.67; 95% CI 2.19\u20136.15). Definitive local salvage therapies were feasible in the majority of the patients with local\u2013regional failure, and uncommonly in patients with distant metastases, with an estimated second-line progression free survival of 67.8% at two years. Competing oncological risks and age were significantly more important for patients\u2019 survival compared to primary disease recurrence.<\/jats:p>","DOI":"10.3390\/biomedicines10102446","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:07:43Z","timestamp":1665187663000},"page":"2446","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ultra-Hypofractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer: Clinical Outcomes, Patterns of Recurrence, Feasibility of Definitive Salvage Treatment, and Competing Oncological Risk"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4375-0827","authenticated-orcid":false,"given":"Marcin","family":"Miszczyk","sequence":"first","affiliation":[{"name":"IIIrd Radiotherapy and Chemotherapy Department, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Wybrze\u017ce Armii Krajowej 15, 44-102 Gliwice, Poland"},{"name":"Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, W\u00e4hringer G\u00fcrtel 18-20, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3868-1051","authenticated-orcid":false,"given":"Monika","family":"Szo\u0142tysik","sequence":"additional","affiliation":[{"name":"IIIrd Radiotherapy and Chemotherapy Department, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Wybrze\u017ce Armii Krajowej 15, 44-102 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Hasterok","sequence":"additional","affiliation":[{"name":"IIIrd Radiotherapy and Chemotherapy Department, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Wybrze\u017ce Armii Krajowej 15, 44-102 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor","family":"Goldner","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, W\u00e4hringer G\u00fcrtel 18-20, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Rajwa","sequence":"additional","affiliation":[{"name":"Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, W\u00e4hringer G\u00fcrtel 18-20, 1090 Vienna, Austria"},{"name":"Department of Urology, Medical University of Silesia, 3-go Maja 13-15, 41-800 Zabrze, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Namys\u0142-Kaletka","sequence":"additional","affiliation":[{"name":"Radiotherapy Department, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Wybrze\u017ce Armii Krajowej 15, 44-102 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Napieralska","sequence":"additional","affiliation":[{"name":"Radiotherapy Department, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Wybrze\u017ce Armii Krajowej 15, 44-102 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0178-1756","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Kraszkiewicz","sequence":"additional","affiliation":[{"name":"Radiotherapy Department, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Wybrze\u017ce Armii Krajowej 15, 44-102 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"St\u0105p\u00f3r-Fudzi\u0144ska","sequence":"additional","affiliation":[{"name":"Treatment Planning Department, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Wybrze\u017ce Armii Krajowej 15, 44-102 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart\u0142omiej","family":"Tomasik","sequence":"additional","affiliation":[{"name":"Radiotherapy Department, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Wybrze\u017ce Armii Krajowej 15, 44-102 Gliwice, Poland"},{"name":"Department of Oncology and Radiotherapy, Faculty of Medicine, Medical University of Gda\u0144sk, Smoluchowskiego 17, 80-214 Gdansk, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Wo\u017aniak","sequence":"additional","affiliation":[{"name":"Radiotherapy Department, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Wybrze\u017ce Armii Krajowej 15, 44-102 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"G\u0142owacki","sequence":"additional","affiliation":[{"name":"Radiotherapy Department, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Wybrze\u017ce Armii Krajowej 15, 44-102 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7481-2621","authenticated-orcid":false,"given":"Konrad","family":"Kamini\u00f3w","sequence":"additional","affiliation":[{"name":"IIIrd Radiotherapy and Chemotherapy Department, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Wybrze\u017ce Armii Krajowej 15, 44-102 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5523-8866","authenticated-orcid":false,"given":"Matthias","family":"Moll","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, W\u00e4hringer G\u00fcrtel 18-20, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141ukasz","family":"Magrowski","sequence":"additional","affiliation":[{"name":"IIIrd Radiotherapy and Chemotherapy Department, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Wybrze\u017ce Armii Krajowej 15, 44-102 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Majewski","sequence":"additional","affiliation":[{"name":"Radiotherapy Department, Maria Sk\u0142odowska-Curie National Research Institute of Oncology, Wybrze\u017ce Armii Krajowej 15, 44-102 Gliwice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer","volume":"375","author":"Donovan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/bju.15739","article-title":"Functional and Quality of Life Outcomes of Localised Prostate Cancer Treatments (Prostate Testing for Cancer and Treatment [ProtecT] Study)","volume":"130","author":"Lane","year":"2022","journal-title":"BJU Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_5","first-page":"02405","article-title":"The Impact of a Statewide Active Surveillance Initiative: A Roadmap for Increasing Active Surveillance Utilization Nationwide","volume":"S0302\u20132838","author":"Vince","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1311593","article-title":"Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer","volume":"370","author":"Holmberg","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The Diagnosis and Treatment of Prostate Cancer: A Review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial","volume":"38","author":"Palma","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s11547-021-01352-w","article-title":"Stereotactic Body Radiotherapy for Oligometastatic Castration Sensitive Prostate Cancer Using 1.5 T MRI-Linac: Preliminary Data on Feasibility and Acute Patient-Reported Outcomes","volume":"126","author":"Mazzola","year":"2021","journal-title":"La Radiol. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A Systematic Review and Meta-Analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER)","volume":"80","author":"Valle","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Foerster, R., Zwahlen, D.R., Buchali, A., Tang, H., Schroeder, C., Windisch, P., Vu, E., Akbaba, S., Bostel, T., and Sprave, T. (2021). Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review. Cancers, 13.","DOI":"10.3390\/cancers13040759"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","article-title":"Fractionation and Protraction for Radiotherapy of Prostate Carcinoma","volume":"43","author":"Brenner","year":"1999","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0360-3016(01)01607-8","article-title":"Is Alpha\/Beta for Prostate Tumors Really Low?","volume":"50","author":"Fowler","year":"2001","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2005.06.009","article-title":"The Alpha\/Beta Ratio for Prostate Cancer: What Is It, Really?","volume":"76","author":"Bentzen","year":"2005","journal-title":"Radiother. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijrobp.2012.03.004","article-title":"Meta-Analysis of the Alpha\/Beta Ratio for Prostate Cancer in the Presence of an Overall Time Factor: Bad News, Good News, or No News?","volume":"85","author":"Vogelius","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-Modulated Fractionated Radiotherapy versus Stereotactic Body Radiotherapy for Prostate Cancer (PACE-B): Acute Toxicity Findings from an International, Randomised, Open-Label, Phase 3, Non-Inferiority Trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-Hypofractionated versus Conventionally Fractionated Radiotherapy for Prostate Cancer: 5-Year Outcomes of the HYPO-RT-PC Randomised, Non-Inferiority, Phase 3 Trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1533033819870815","DOI":"10.1177\/1533033819870815","article-title":"Stereotactic Ablative Radiotherapy for Prostate Cancer-The Treatment Results of 500 Patients and Analysis of Failures","volume":"18","author":"Miszczyk","year":"2019","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.radonc.2013.12.012","article-title":"Second Primary Cancers after Radiation for Prostate Cancer: A Systematic Review of the Clinical Data and Impact of Treatment Technique","volume":"110","author":"Murray","year":"2014","journal-title":"Radiother. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1113162","article-title":"Radical Prostatectomy versus Observation for Localized Prostate Cancer","volume":"367","author":"Wilt","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e2223025","DOI":"10.1001\/jamanetworkopen.2022.23025","article-title":"Assessment of Second Primary Cancer Risk Among Men Receiving Primary Radiotherapy vs Surgery for the Treatment of Prostate Cancer","volume":"5","author":"Bagshaw","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"i851","DOI":"10.1136\/bmj.i851","article-title":"Second Malignancies after Radiotherapy for Prostate Cancer: Systematic Review and Meta-Analysis","volume":"352","author":"Wallis","year":"2016","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.ijrobp.2007.11.067","article-title":"Virtual HDRSM CyberKnife Treatment for Localized Prostatic Carcinoma: Dosimetry Comparison With HDR Brachytherapy and Preliminary Clinical Observations","volume":"70","author":"Fuller","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1111\/j.1464-410X.2012.11385.x","article-title":"Secondary Cancers after Intensity-Modulated Radiotherapy, Brachytherapy and Radical Prostatectomy for the Treatment of Prostate Cancer: Incidence and Cause-Specific Survival Outcomes According to the Initial Treatment Intervention","volume":"110","author":"Zelefsky","year":"2012","journal-title":"BJU Int."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Hagmann, S., Ramakrishnan, V., Tamalunas, A., Hofmann, M., Vandenhirtz, M., Vollmer, S., Hug, J., Niggli, P., Nocito, A., and Kubik-Huch, R.A. (2022). Two Decades of Active Surveillance for Prostate Cancer in a Single-Center Cohort: Favorable Outcomes after Transurethral Resection of the Prostate. Cancers, 14.","DOI":"10.3390\/cancers14020368"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"20150981","DOI":"10.1259\/bjr.20150981","article-title":"Low Dose Rate Brachytherapy (LDR-BT) as Monotherapy for Early Stage Prostate Cancer in Italy: Practice and Outcome Analysis in a Series of 2237 Patients from 11 Institutions","volume":"89","author":"Fellin","year":"2016","journal-title":"Br. J. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5114\/jcb.2021.108590","article-title":"High-Dose-Rate Fractionated Brachytherapy Monotherapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis","volume":"13","author":"Anderson","year":"2021","journal-title":"J. Contemp. Brachyther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.radonc.2015.09.019","article-title":"Toxicity and Quality of Life after High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer","volume":"117","author":"Aluwini","year":"2015","journal-title":"Radiother. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijrobp.2010.05.056","article-title":"Long-Term Results of a Phase II Trial of Ultrasound-Guided Radioactive Implantation of the Prostate for Definitive Management of Localized Adenocarcinoma of the Prostate (RTOG 98-05)","volume":"81","author":"Lawton","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.radonc.2021.02.028","article-title":"Ultra-Hypofractionated Radiotherapy for Low- and Intermediate Risk Prostate Cancer: High-Dose-Rate Brachytherapy vs Stereotactic Ablative Radiotherapy","volume":"158","author":"Tsang","year":"2021","journal-title":"Radiother. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1470-2045(20)30730-0","article-title":"Intermediate Clinical Endpoints for Surrogacy in Localised Prostate Cancer: An Aggregate Meta-Analysis","volume":"22","author":"Gharzai","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bju.15507","article-title":"Systemic therapies for metastatic hormone-sensitive prostate cancer: Network meta-analysis","volume":"129","author":"Mori","year":"2022","journal-title":"BJU Int."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Cattrini, C., Castro, E., Lozano, R., Zanardi, E., Rubagotti, A., Boccardo, F., and Olmos, D. (2019). Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer. Cancers, 11.","DOI":"10.3390\/cancers11091355"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"368","DOI":"10.5534\/wjmh.210072","article-title":"Genomic Profiling of Prostate Cancer: An Updated Review","volume":"40","author":"Hatano","year":"2022","journal-title":"World J. Mens. Health"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Miszczyk, M., Rembak-Szynkiewicz, J., Magrowski, \u0141., Stawiski, K., Namys\u0142-Kaletka, A., Napieralska, A., Kraszkiewicz, M., Wo\u017aniak, G., St\u0105p\u00f3r-Fudzi\u0144ska, M., and G\u0142owacki, G. (2022). The Prognostic Value of PI-RADS Score in CyberKnife Ultra-Hypofractionated Radiotherapy for Localized Prostate Cancer. Cancers, 14.","DOI":"10.3390\/cancers14071613"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5114\/pjp.2022.117174","article-title":"Grade Migration and Important Prognostic Factors in a Pathology Specimen for Radical Radiotherapy in Prostate Cancer Patients","volume":"73","author":"Majewski","year":"2022","journal-title":"Pol. J. Pathol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/10\/2446\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:44:39Z","timestamp":1760143479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/10\/2446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["biomedicines10102446"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10102446","relation":{},"ISSN":["2227-9059"],"issn-type":[{"type":"electronic","value":"2227-9059"}],"subject":[],"published":{"date-parts":[[2022,9,30]]}}}